Table 2.
Risk of the development of eGFR <60 mL/min/1.73 m2 according to quartiles of sCr levels in female and male subjects.
| Model 1 | Model 2 | Model 3 | Model 4 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Incidence of CKD (%) a | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | |
| Quartiles of sCr | |||||||||
| Female | |||||||||
| Q1 (n = 2083) | 96 (4.6) | Reference | Reference | Reference | Reference | ||||
| Q2 (n = 1325) | 146 (11.0) | 2.50 (1.93–3.24) | <0.001 | 2.59 (1.90–3.53) | <0.001 | 2.62 (1.91–3.59) | <0.001 | 2.57 (1.83–3.60) | <0.001 |
| Q3 (n = 862) | 133 (15.4) | 3.89 (2.99–5.06) | <0.001 | 3.51 (2.56–4.81) | <0.001 | 3.56 (2.58–4.92) | <0.001 | 3.79 (1.83–5.35) | <0.001 |
| Q4 (n = 684) | 112 (16.4) | 4.20 (3.20–5.51) | <0.001 | 4.21 (3.04–5.84) | <0.001 | 4.19 (3.00–5.85) | <0.001 | 4.71 (3.29–6.74) | <0.001 |
| Male | |||||||||
| Q1 (n = 1457) | 28 (1.9) | Reference | Reference | Reference | Reference | ||||
| Q2 (n = 995) | 56 (5.6) | 2.88 (1.83–4.53) | <0.001 | 3.18 (1.90–5.34) | <0.001 | 3.08 (1.82–5.20) | <0.001 | 3.30 (1.90–5.74) | <0.001 |
| Q3 (n = 956) | 84 (8.8) | 4.64 (3.03–7.12) | <0.001 | 5.79 (3.57–9.39) | <0.001 | 6.04 (3.72–9.81) | <0.001 | 6.75 (4.03–11.30) | <0.001 |
| Q4 (n = 1083) | 124 (11.4) | 6.43 (4.27–9.69) | <0.001 | 10.31 (6.49–16.38) | <0.001 | 11.21 (7.02–17.90) | <0.001 | 12.77 (7.69–21.23) | <0.001 |
ap for trend <0.001. Model 1: Unadjusted model. Model 2: Adjusted for age and muscle mass. Model 3: Adjusted for Model 2 + BMI, SBP, smoking and alcohol status, history of HTN, DM, and CVDs. Model 4: Adjusted for Model 3 + hemoglobin, fasting plasma glucose, serum albumin, total cholesterol, CRP, and proteinuria. CKD: chronic kidney disease; HR: hazard ratio; CI: confidence interval.